Novavax sees weak Covid vaccine sales
Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. The Maryland biotech has agreed to pay $123.8 million to end a COVID vaccine supply pact with the UK Health Security ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
The vaccine approved for emergency authorization is manufactured by pharmaceutical company Novavax, with updated vaccines from ... the most current COVID-19 variant. “It’s not bivalent, which ...
Novavax will refund $123.8 million to the UK agency in quarterly payments of $10.3 million over three years. The two parties initially entered into a COVID-19 vaccine supply deal in 2020.
This year, instead of bivalent shots, both Pfizer and Moderna are monovalent ... Both vaccines have shown broad efficacy against several currently circulating strains. The Novavax vaccine uses ...
(The Novavax vaccine works in a similar way to ... Previously, VSD identified a statistical signal for the Pfizer/BioNTech bivalent vaccine in 2022-2023 in people 65 years and older, but ...
TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback